triazoles has been researched along with exenatide in 117 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (31.62) | 29.6817 |
| 2010's | 80 (68.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drucker, DJ; Nauck, MA | 1 |
| Campbell, KM; Taylor, JR | 1 |
| Winkler, G | 1 |
| Klein, HH; Meier, JJ; Schmidt, WE | 1 |
| Scheen, AJ | 1 |
| Amori, RE; Lau, J; Pittas, AG | 1 |
| Whitehill, D | 1 |
| Mirza, SA | 1 |
| Dailey, GE | 1 |
| Singer, M | 1 |
| Ahrén, B | 1 |
| Mikhail, N | 1 |
| Choe, HM; Sweet, BV; VanDeKoppel, S | 1 |
| Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H | 1 |
| Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Bunck, MC; Diamant, M | 1 |
| DeFronzo, RA; Guan, X; Holcombe, JH; MacConell, L; Okerson, T; Viswanathan, P | 1 |
| Drucker, DJ; Duez, H; Giacca, A; Lewis, GF; Smith, AC; Szeto, L; Xiao, C | 1 |
| Davidson, JA; Gross, JL; Parente, EB | 1 |
| Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E | 1 |
| Seissler, J | 1 |
| Egan, JM; Kim, W | 1 |
| Siddiqui, NI | 1 |
| Boye, KS; Fabunmi, R; Lage, MJ; Misurski, DA | 1 |
| Nicolucci, A; Rossi, MC | 1 |
| Arnold Chan, K; Dore, DD; Seeger, JD | 1 |
| Gallwitz, B | 1 |
| Miuchi, M; Miyagawa, J; Nanba, M | 1 |
| Cognard, E; Shepherd, PR; Smith, GC; Vickers, MH | 1 |
| Drucker, DJ; Hansotia, T; Longuet, C; Maida, A; Seino, Y | 1 |
| D'Alessio, D; Jessen, L | 1 |
| Freeman, JS | 2 |
| Hoerger, T; Pogach, L; Rajan, M; Sinha, A | 1 |
| Fontés, G; Hagman, DK; Latour, MG; Poitout, V; Semache, M | 1 |
| Peters, A | 1 |
| Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S | 1 |
| Berria, R; Davis, KL; Horton, ES; Silberman, C | 1 |
| Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q | 1 |
| Guerci, B; Halter, C | 1 |
| Unger, J | 1 |
| Kuritzky, L | 1 |
| Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P | 1 |
| Meier, JJ; Nauck, MA | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Svec, F | 1 |
| Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N | 1 |
| Chen, W; Garg, R; Pendergrass, M | 1 |
| Borelli, MI; Del Zotto, H; Flores, LE; Francini, F; Gagliardino, JJ; Madrid, VG; Maiztegui, B; Massa, ML; Raschia, MA; Rebolledo, OR | 1 |
| Garber, AJ | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Boudes, P; Viereck, C | 1 |
| Best, JH; Garrison, LP; Li, Y; Malloy, J; Peyrot, M; Rubin, RR; Yan, P | 1 |
| Jellinger, PS | 1 |
| Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV | 1 |
| Spellman, CW | 1 |
| Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Hawkes, N | 1 |
| Doggrell, SA | 1 |
| Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R | 1 |
| Berg, JK; Gray, AL; Heilmann, CR; Holcombe, JH; Shenouda, SK | 1 |
| Gundert-Remy, U; Spranger, J; Stammschulte, T | 1 |
| Hurren, KM; Pinelli, NR | 1 |
| DeYoung, MB; Herbert, P; MacConell, L; Sarin, V; Trautmann, M | 1 |
| Jermendy, G | 1 |
| Brubaker, PL; Grieco, A; Iakoubov, R; Lauffer, LM; Sangle, GV; Trivedi, S | 1 |
| Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM | 1 |
| Chen, W; Fenton, C; Haffner, SM; Pendergrass, M | 1 |
| Best, JH; DeYoung, MB; Gaebler, JA; Guillermin, AL; Lloyd, A; Samyshkin, Y | 1 |
| Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB | 1 |
| Nauck, MA | 1 |
| Davies, M; Speight, J | 1 |
| Ahrén, B; Deacon, CF; Mannucci, E | 1 |
| Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM | 1 |
| Gupta, S | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Buse, J; Jensen, KH; Niswender, K; Pi-Sunyer, X; Russell-Jones, D; Toft, AD; Zinman, B | 1 |
| Chen, ZY; Huang, Y; Lam, KS; Lau, CW; Liu, J; Liu, L; Ng, CF; Pu, Y; Tian, XY; Wang, YX; Wong, WT; Xu, A; Xu, G; Yao, X; Zhu, Z | 1 |
| Chen, M; Guo, Z; Hao, J; Houze, J; Lin, DC; Lopez, E; Luo, J; Ma, Z; Nguyen, K; Rulifson, IC; Tian, B; Tian, L; Tran, T; Wang, Y; Zhang, Y | 1 |
| Hansen, LS; Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS; Rosenkilde, MM; Viby, NE | 1 |
| Baruah, MP; Chaudhury, T; Dharmalingam, M; Sethi, BK | 1 |
| Chang, HY; Clark, JM; Richards, TM; Segal, JB; Singh, S; Weiner, JP | 1 |
| Gale, EA | 1 |
| Cohen, D | 1 |
| Grunberger, G | 1 |
| Hari Kumar, KV; Prusty, P; Shaikh, A | 1 |
| Drake, AJ; Iyer, SN; Mendez, CE; Tanenberg, RJ; West, RL | 1 |
| Bergeson, JG; Graham, J; Louder, A; Ward, M; Worley, K | 1 |
| Han, J; Malloy, J; Meloni, A | 1 |
| Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
| Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
| Harja, E; Lord, J; Skyler, JS | 1 |
| Chang, CL; Chang, HW; Chang, LT; Chen, HH; Chen, YL; Chen, YT; Leu, S; Sun, CK; Sung, PH; Tsai, TH; Yang, CC; Yip, HK; Zhen, YY | 1 |
| Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P | 1 |
| Anand, S; Bhatia, T; Olaywi, M; Singhal, S | 1 |
| Gao, Y; Huang, Y; Lau, CW; Liu, J; Liu, L; Ng, CF; Tian, XY; Wong, WT; Xu, A; Xu, G; Yao, X | 1 |
| Nistala, R; Rao, A | 1 |
| Rouse, R; Stewart, S; Xu, L; Zhang, J | 1 |
| Tibaldi, JM | 1 |
| Duke, J; Li, X; Zhang, Z | 1 |
| Fuller, CS; Gallop, R; Gudipaty, L; Rickels, MR; Rosenfeld, NK; Schutta, MH | 1 |
| Kourlaba, G; Maniadakis, N; Melidonis, A; Tzanetakos, C; Verras, C | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Fukushima, A; Furihata, T; Harashima, S; Homma, T; Kadoguchi, T; Kinugawa, S; Masaki, Y; Matsumoto, J; Matsushima, S; Mizushima, W; Okita, K; Takada, S; Takahashi, M; Tanaka, S; Tsutsui, H; Yokota, T | 1 |
46 review(s) available for triazoles and exenatide
| Article | Year |
|---|---|
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2006 |
Diabetes drug update: how 4 new options stack up.
Topics: Administration, Inhalation; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Exenatide; Family Practice; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Islet Amyloid Polypeptide; Male; Peptides; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2007 |
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
[New concepts in the treatment of type 2 diabetes].
Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Using prandial insulin to achieve glycemic control in type 2 diabetes.
Topics: Algorithms; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Postprandial Period; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
Managed care perspective on three new agents for type 2 diabetes.
Topics: Amyloid; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Managed Care Programs; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
[New drugs; exenatide and sitagliptin].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
Incretin-based therapies in type 2 diabetes: a review of clinical results.
Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
The role of incretins in glucose homeostasis and diabetes treatment.
Topics: Animals; Diabetes Mellitus; Exenatide; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2008 |
[The value of incretin based therapies].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
[Incretin related agents for treatment of diabetes mellitus].
Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2009 |
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Incretin-based therapies: review of current clinical trial data.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
Incretin physiology and its role in type 2 diabetes mellitus.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin | 2010 |
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.
Topics: Algorithms; Chronic Disease; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Lactic Acid; Peptides; Pioglitazone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Medication Adherence; Patient Satisfaction; Peptides; Pyrazines; Self Care; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2012 |
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Male; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
Immunotherapies in diabetes mellitus type 1.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Azathioprine; Basiliximab; Chaperonin 60; Cyclosporine; Daclizumab; Diabetes Mellitus, Type 1; Diet; Etanercept; Exenatide; Fatty Acids, Unsaturated; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Insulin; Interferon-alpha; Interleukin 1 Receptor Antagonist Protein; Islets of Langerhans Transplantation; Niacinamide; Peptide Fragments; Peptides; Primary Prevention; Pyrazines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rituximab; Secondary Prevention; Sitagliptin Phosphate; Tertiary Prevention; Triazoles; Venoms; Vitamin D; Vitamins | 2012 |
Liraglutide in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Molecular Structure; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2013 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
Type 1 diabetes and cardiovascular disease.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
Topics: Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Liver; Non-alcoholic Fatty Liver Disease; Peptides; Pyrazines; Sitagliptin Phosphate; Transaminases; Treatment Outcome; Triazoles; Venoms | 2013 |
Is there a role for the incretin system in blood pressure regulation?
Topics: Animals; Blood Pressure; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypertension; Incretins; Oxidative Stress; Peptides; Pyrazines; Renin-Angiotensin System; Sitagliptin Phosphate; T-Lymphocytes, Regulatory; Triazoles; Venoms | 2014 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
12 trial(s) available for triazoles and exenatide
| Article | Year |
|---|---|
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake; Exenatide; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Stomach; Triazoles; Venoms | 2008 |
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Health Status; Humans; Hypoglycemic Agents; Male; Mental Health; Middle Aged; Patient Satisfaction; Peptides; Pioglitazone; Pyrazines; Quality of Life; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
The metabolic syndrome influences the response to incretin-based therapies.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2011 |
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms; Young Adult | 2011 |
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Weight Loss | 2013 |
Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
Topics: Adult; Diabetes Mellitus, Type 1; Exenatide; Female; Humans; Insulin; Male; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Young Adult | 2013 |
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Peptides; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; Venoms; Young Adult | 2014 |
59 other study(ies) available for triazoles and exenatide
| Article | Year |
|---|---|
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2007 |
[New class of oral antidiabetic drugs. Effective in combination with metformin].
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Treatment of type 2 diabetes mellitus and the incretin system.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms | 2007 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Type 2 diabetes drug boom: is newer better?
Topics: Amyloid; Diabetes Mellitus; Exenatide; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Type 2 diabetes: the end of clinical inertia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2007 |
Management of comorbid diabetes and cancer.
Topics: Ambulatory Care; Amyloid; Comorbidity; Diabetes Mellitus; Exenatide; Humans; Hypoglycemic Agents; Inpatients; Insulin; Islet Amyloid Polypeptide; Neoplasms; Peptides; Practice Guidelines as Topic; Pyrazines; Quality of Life; Risk Factors; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2007 |
Three new drugs for type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin | 2008 |
[New drugs; exenatide and sitagliptin].
Topics: Exenatide; Glucagon-Like Peptide 1; Humans; Insulin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2008 |
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
Topics: Animals; Blood Glucose; Body Weight; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucose Clamp Technique; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Mice; Mice, Inbred C57BL; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin | 2008 |
Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cost Savings; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Costs; Emergency Service, Hospital; Exenatide; Female; Glycated Hemoglobin; Health Care Costs; Health Services Research; Humans; Hypoglycemic Agents; Insurance Claim Review; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Regression Analysis; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms | 2009 |
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
Topics: Adolescent; Adult; Databases, Factual; Exenatide; Female; Glyburide; Humans; Hypoglycemic Agents; Insurance, Health; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Safety; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult | 2009 |
Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Body Composition; Body Weight; Clozapine; Dibenzothiazepines; Dietary Fats; Disease Models, Animal; Eating; Exenatide; Food Preferences; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Peptides; Pyrazines; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Topics: Animals; Apoptosis; Blood Glucose; Caspase 3; Cell Line; Cell Proliferation; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Peptides; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2009 |
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2009 |
The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.
Topics: Animals; Blood Glucose; Cell Proliferation; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin-Secreting Cells; Mice; Peptides; Pyrazines; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2009 |
Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Peptides; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
Topics: Analysis of Variance; Animals; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Exenatide; Fat Emulsions, Intravenous; Gene Expression; Glucagon-Like Peptide 1; Glucose; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Peptides; Pyrazines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Multivariate Analysis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms | 2010 |
[New hypoglycemic agents in type 2 diabetes].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2010 |
Choosing among the incretin agents and why it matters.
Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pancreatitis; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.
Topics: Animals; Apoptosis; Blood Glucose; Body Weight; Diet; Dipeptidyl-Peptidase IV Inhibitors; Drinking; Drug Evaluation, Preclinical; Eating; Exenatide; Fatty Liver; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metabolic Syndrome; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms | 2011 |
Journal withdraws article after complaints from drug manufacturers.
Topics: Diabetes Mellitus, Type 2; Drug Industry; Editorial Policies; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Periodicals as Topic; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
GLP-1-based therapies: the dilemma of uncertainty.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms | 2011 |
Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
Topics: Exenatide; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Topics: Animals; Animals, Newborn; Cell Line; Cyclic AMP; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Exenatide; Extracellular Signal-Regulated MAP Kinases; Glucagon-Like Peptide 1; Humans; Ionomycin; Mice; Molecular Structure; Peptides; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
Topics: Acute Kidney Injury; Adolescent; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Labeling; Exenatide; Female; Humans; Incidence; Male; Middle Aged; Peptides; Proportional Hazards Models; Pyrazines; Retrospective Studies; Risk Assessment; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult | 2012 |
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
Topics: Adult; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Humans; Hypoglycemic Agents; Long-Term Care; Male; Markov Chains; Middle Aged; Models, Theoretical; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; United States; Venoms | 2012 |
Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Topics: Aged; Aged, 80 and over; Animals; Blood Pressure; Cells, Cultured; Cyclic AMP; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypertension; In Vitro Techniques; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Nitric Oxide; Peptides; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Glucagon; Regional Blood Flow; Renal Artery; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Humans; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Mice; Mice, Nude; Nateglinide; Peptides; Phenylalanine; Pyrazines; Sitagliptin Phosphate; Specific Pathogen-Free Organisms; Triazoles; Venoms | 2013 |
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Adenoma; Anatomy, Cross-Sectional; Animals; Chlorocebus aethiops; Colon; Colonic Neoplasms; COS Cells; Cyclic AMP; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptide-2 Receptor; Hypoglycemic Agents; Intestinal Mucosa; Intestine, Small; Liraglutide; Mice; Mice, Inbred C57BL; Organ Size; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Transfection; Triazoles; Venoms | 2012 |
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Topics: Acute Disease; Adolescent; Adult; Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Hospitalization; Humans; Logistic Models; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
GLP-1 based agents and acute pancreatitis : drug safety falls victim to the three monkey paradigm.
Topics: Acute Disease; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metaphor; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2013 |
Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
Topics: Acute Disease; Animals; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Exenatide; Humans; Hypoglycemic Agents; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Pancreatitis associated with incretin-based therapies.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Incretins; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Exenatide; Female; Health Care Costs; Humans; Hypoglycemic Agents; Linear Models; Male; Medicare Part D; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Topics: Adolescent; Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hyperplasia; Hypoglycemic Agents; Incretins; Male; Middle Aged; Models, Statistical; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Tissue Banks; Triazoles; Venoms; Young Adult | 2013 |
Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction.
Topics: Animals; Biomarkers; Creatinine; Exenatide; Inflammation; Kidney; Male; Oxidative Stress; Peptides; Proteinuria; Pyrazines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress.
Topics: Animals; Cyclooxygenase 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endothelium, Vascular; Exenatide; Gene Expression Regulation; Humans; Hypertension; Ion Channels; Male; Mice; Mitochondria; Mitochondrial Proteins; Models, Biological; Oxidative Stress; Peptides; Pyrazines; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Renal Artery; Sitagliptin Phosphate; Triazoles; Uncoupling Protein 2; Vasoconstriction; Venoms | 2014 |
High fat diet and GLP-1 drugs induce pancreatic injury in mice.
Topics: Acute Disease; Animals; Apoptosis; Atrophy; Diet, High-Fat; Exenatide; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Necrosis; Pancreas; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2014 |
Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis.
Topics: Adult; Aged; Cohort Studies; Databases, Factual; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms; Young Adult | 2014 |
Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide 1; Greece; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Male; Mice, Inbred C57BL; Mitochondria; Muscle, Skeletal; Myocardial Infarction; Organelle Biogenesis; Peptides; Triazoles; Venoms | 2016 |